Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6 - PubMed (original) (raw)
Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6
H S Oldenburg et al. Eur J Immunol. 1993 Aug.
Abstract
Cachexia and the acute-phase response are common manifestations of inflammation and are presumed to be the product of increased synthesis and release of cytokines, including tumor necrosis factor (TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6). IL-1 receptor blockade has been previously shown to attenuate the weight loss, anorexia and acute-phase protein responses associated with a turpentine abscess. However, IL-1 receptor blockade was also associated with a reduced plasma IL-6 response, suggesting that the benefit achieved by IL-1 receptor blockade may be mediated by reduced systemic IL-6 production. To gain a better understanding of the role of IL-6 in this model of inflammation, C57BL/6 mice were passively immunized with either a monoclonal anti-IL-6 antibody (20F3), an anti-IL-1 type I receptor monoclonal antibody (35F5), a non-immune rat IgG, or a combined therapy of 35F5 and 20F3, before receiving a sterile turpentine abscess. IL-6 or IL-1 receptor blockade equally spared body weight and food intake. Compared to IL-1 receptor blockade, passive immunization against IL-6 further reduced the hepatic acute-phase protein response, as represented by serum amyloid P and complement 3. Combined blockade of IL-6 and IL-1 receptor did not result in a further sparing of body weights or improvement of food intake. These results confirm that IL-1 contributes to host cachexia and the acute-phase response following a turpentine abscess, but also show that these actions are dependent upon an IL-6 response. We conclude that the influence of IL-1 on cachexia and the acute-phase response is mediated, at least in part, through IL-6 and, thus, IL-6 may play a pivotal role in the cachexia and acute-phase response to inflammation.
Similar articles
- Interleukin 1 binding to its type I, but not type II receptor, modulates the in vivo acute phase response.
Oldenburg HS, Pruitt JH, Lazarus DD, Rogy MA, Chizzonite R, Lowry SF, Moldawer LL. Oldenburg HS, et al. Cytokine. 1995 Aug;7(6):510-6. doi: 10.1006/cyto.1995.0069. Cytokine. 1995. PMID: 8580366 - Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia.
Gelin J, Moldawer LL, Lönnroth C, Sherry B, Chizzonite R, Lundholm K. Gelin J, et al. Cancer Res. 1991 Jan 1;51(1):415-21. Cancer Res. 1991. PMID: 1703040 - Interleukin 6, but not ciliary neurotrophic factor or leukaemia inhibitory factor, is responsible for the acute phase response to turpentine-induced myositis.
Kaibara A, Espat NJ, Auffenberg T, Abouhamze AS, Martin D, Kalra S, Moldawer LL. Kaibara A, et al. Cytokine. 1998 Jun;10(6):452-6. doi: 10.1006/cyto.1997.0313. Cytokine. 1998. PMID: 9632532 - Cytokines and the hepatic acute-phase response.
Ramadori G, Christ B. Ramadori G, et al. Semin Liver Dis. 1999;19(2):141-55. doi: 10.1055/s-2007-1007106. Semin Liver Dis. 1999. PMID: 10422197 Review. - Are cytokines possible mediators of cancer cachexia?
Noguchi Y, Yoshikawa T, Matsumoto A, Svaninger G, Gelin J. Noguchi Y, et al. Surg Today. 1996;26(7):467-75. doi: 10.1007/BF00311551. Surg Today. 1996. PMID: 8840426 Review.
Cited by
- Cachexia: A systemic consequence of progressive, unresolved disease.
Ferrer M, Anthony TG, Ayres JS, Biffi G, Brown JC, Caan BJ, Cespedes Feliciano EM, Coll AP, Dunne RF, Goncalves MD, Grethlein J, Heymsfield SB, Hui S, Jamal-Hanjani M, Lam JM, Lewis DY, McCandlish D, Mustian KM, O'Rahilly S, Perrimon N, White EP, Janowitz T. Ferrer M, et al. Cell. 2023 Apr 27;186(9):1824-1845. doi: 10.1016/j.cell.2023.03.028. Cell. 2023. PMID: 37116469 Free PMC article. Review. - Low skeletal muscle radiodensity and neutrophil-to-lymphocyte ratio as predictors of poor outcome in patients with COVID-19.
Padilha DMH, Mendes MCS, Lascala F, Silveira MN, Pozzuto L, Santos LAO, Guerra LD, Moreira RCL, Branbilla SR, Junior ADC, Duarte MBO, Moretti ML, Carvalheira JBC. Padilha DMH, et al. Sci Rep. 2022 Sep 20;12(1):15718. doi: 10.1038/s41598-022-20126-6. Sci Rep. 2022. PMID: 36127500 Free PMC article. - Malnutrition in Older Adults-Recent Advances and Remaining Challenges.
Norman K, Haß U, Pirlich M. Norman K, et al. Nutrients. 2021 Aug 12;13(8):2764. doi: 10.3390/nu13082764. Nutrients. 2021. PMID: 34444924 Free PMC article. Review. - Immune Checkpoint Inhibitors in the Aged.
Isaacs J, Antonia S, Clarke J. Isaacs J, et al. Curr Oncol Rep. 2021 Aug 3;23(10):115. doi: 10.1007/s11912-021-01106-x. Curr Oncol Rep. 2021. PMID: 34342733 Review. - Therapeutic efficacy of IL-17A neutralization with corticosteroid treatment in a model of antigen-driven mixed-granulocytic asthma.
Menson KE, Mank MM, Reed LF, Walton CJ, Van Der Vliet KE, Ather JL, Chapman DG, Smith BJ, Rincon M, Poynter ME. Menson KE, et al. Am J Physiol Lung Cell Mol Physiol. 2020 Oct 1;319(4):L693-L709. doi: 10.1152/ajplung.00204.2020. Epub 2020 Aug 12. Am J Physiol Lung Cell Mol Physiol. 2020. PMID: 32783616 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources